also on other fortune lists

company facts

f500 stats

Fortune 500

Simon Dawson — Bloomberg via Getty Images




Pfizer will have to find a way to boost profits that doesn’t entail cutting its tax bill. In early 2016, the U.S. Treasury Department scuttled its planned inversion with Ireland-based Allergan, which would have moved the Big Pharma company’s headquarters overseas. The New York-based drug maker, which benefited from its blockbuster medication Lipitor before it went off patent, was hoping to reduce its tax rate through the $150 billion deal, which would have been the largest pharmaceutical merger in history. Instead, Pfizer will have to focus on reviving its core business, which has been in decline. The company’s sales dropped 1.5% in 2015 as it still deals with the impact of patent expirations on some of its biggest drugs. Its profits, meanwhile, fell nearly 24%, largely due to a surge in acquisition-related costs, which more than quintupled from the previous year due to Pfizer’s purchase of Hospira in early 2015. Pfizer’s stock fell 14.2% in 2015, a result of its performance as well as concerns that drug price regulation could hamper its profitability.


Ian C. Read


Health Care



HQ Location

New York, NY

Years on Fortune 500 List




Acquired Hospira (2014 rank: 575), Sept. 3, 2015.
Pfizer is also featured in these fortune lists
Key Financials (last fiscal year)
$ millions% change
Revenues ($M)$48,851-1.5%
Profits ($M)$6,960-23.8%
Assets ($M)$167,460
Total Stockholder Equity ($M)$64,720
Market Value — as of March 31, 2016 ($M)$183,298
Profit Ratios
Profit as % of Revenues14.2%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity10.8%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.11
EPS % Change (from 2014)-21.8%
EPS % Change (5 year annual rate)1.7%
EPS % Change (10 year annual rate)0.2%
Total Return
Total Return to Investors (2015)7.1%
Total Return to Investors (5 year, annualized)17.1%
Total Return to Investors (10 year, annualized)7.8%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

Why Broken-Off Mergers Can Be Big Wins for Investors

The stocks of 'target' companies are often better-off single.

Read More →
Pharma Executives Aren't Excited About Trump's Plans to Ease FDA Regulation

They say a robust review process is needed to convince doctors and insurers new drugs have value.

Read More →

Videos about Pfizer

This Is Your Mid-Year Market Recap

What you need to know before making your next investment.

Read More →
Fortune Live for April 7, 2016: Tilman Fertitta, Casper Mattresses, and Hacking Smartphones

We sit down with Tilman Fertitta, Philip Krim, co-founder and CEO of Casper, and teach you how to hack into your smartphone using Play-Doh.

Read More →
Here’s What Congress Can Do About Mega-Mergers

On the heels of Pfizer and Allergan calling off a $160 billion deal

Read More →
Here's How Much Pfizer Paid Allergan Over the Merger Scrap

It would have created the largest drug company in the world.

Read More →